Dt&Cro
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Dt&Cro runs clinical and preclinical trials on behalf of pharmaceutical, medical-device, health-supplement, and cosmetics companies that need independent scientific testing before they can bring a new product to market.
As a full-service contract research organisation (CRO), it handles every stage of the testing pipeline, from early animal-based safety and efficacy studies conducted under internationally recognised good-laboratory-practice standards, through all phases of human clinical trials under good-clinical-practice standards, to regulatory consulting for approvals including the US FDA. Its analytical centre also provides pharmacokinetic and toxicokinetic data used in generic-drug approvals and new-drug development. The company is listed on KOSDAQ, South Korea's technology and small-cap exchange.
Summary is AI-generated and may contain errors · figures from DART filings
Dt&Cro recently opened a dedicated pharmacokinetics and pharmacodynamics centre, expanding its in-house analytical capabilities to include drug-metabolism and disposition testing services.
Dt&Cro in five facts
What does Dt&Cro do?
Dt&Cro runs clinical and preclinical trials on behalf of pharmaceutical, medical-device, health-supplement, and cosmetics companies that need independent scientific testing before they can bring a new product to market.
Where is Dt&Cro listed and in which sector?
Dt&Cro (Korean name: 디티앤씨알오) trades under KRX code 383930 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is Dt&Cro?
Its market capitalisation was US$22.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Dt&Cro's latest annual revenue and operating profit?
For fiscal year 2025, Dt&Cro reported revenue of US$36M, an operating loss of US$4.3M and a net loss of US$2.1M, per its annual report on DART (data retrieved from DART on 2026-06-03). Revenue was up 32.7% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-03
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Court judgment/ruling on litigationOct 7
- Court judgment/ruling on litigationSep 30
- Court judgment/ruling on litigationSep 30
- [Attachment amended] Court judgment/ruling on litigationSep 30
- [Amended] DisclosureSep 29
- [Amended] Conversion price adjustmentSep 29
- [Amended] Court judgment/ruling on litigationSep 28
- [Amended] Court judgment/ruling on litigationSep 28
- Court judgment/ruling on litigationSep 28
- [Amended] Material event report (convertible bonds)
Dt&Cro updated the terms of convertible bonds to raise US$9.81M, about 57.0% of its market value.
Capital raise · Feb 26 - [Amended] Material event report (bonds with warrants)
Dt&Cro updated the terms of bonds with warrants to raise US$4.2M, about 24.4% of its market value.
Capital raise · Feb 26 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Feb 23
- [Amended] Material event report (convertible bonds)
Dt&Cro updated the terms of convertible bonds to raise US$9.52M, about 44.1% of its market value.
Capital raise · Feb 6 - [Amended] Material event report (bonds with warrants)
Dt&Cro updated the terms of bonds with warrants to raise US$4.08M, about 18.9% of its market value.
Capital raise · Feb 6 - Material event report (bonds with warrants)
Dt&Cro disclosed bonds with warrants to raise US$4.11M, about 19.4% of its market value.
Capital raise · Feb 5 - Material event report (convertible bonds)
Dt&Cro disclosed convertible bonds to raise US$9.59M, about 45.2% of its market value.
Capital raise · Feb 5 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Dt&Cro reported separate results for FY2025: revenue of US$33M (+32.7% year on year), an operating loss of US$3.9M and a net loss of US$1.85M.
Earnings · Feb 4 - [Amended] Supply contract signed (voluntary)Supply contract · Jan 21